Literature DB >> 12586769

The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins.

Valeria Ranzi1, Susan O Meakin, Claudia Miranda, Piera Mondellini, Marco A Pierotti, Angela Greco.   

Abstract

The thyroid TRK oncogenes are generated by chromosomal rearrangements juxtaposing the neurotrophic tyrosine receptor kinase type 1 (NTRK1) tyrosine kinase domain to foreign activating sequences. TRK oncoproteins display a constitutive tyrosine kinase activity resulting in the capability to transform NIH3T3 cells. The TRK oncoproteins' signal transduction has been in part elucidated, and it involves several signal transducers activated by the NGF-stimulated NTRK1 receptor. In this paper, we investigate the role of FRS2 and FRS3, two related adapter proteins activated by fibroblast growth factor and NTRK1 receptors, in the signaling of the thyroid TRK-T1 and TRK-T3 oncogenes. By a combination of in vitro and in vivo assays, we demonstrate that both fibroblast growth factor receptor substrate (FRS)2 and FRS3 are recruited and activated by TRK-T1 and TRK-T3. Interaction studies using different TRK-T3 mutants indicate that FRS3 is recruited by the same tyrosine residue interacting with Shc and FRS2. Expression studies show different expression patterns of the FRS adapters in normal and tumor thyroid samples: FRS3 is expressed in both normal and thyroid tumor samples, whereas FRS2 is not expressed in normal thyroid but is differentially expressed in some tumors. Altogether, our data indicate that the FRS2 and FRS3 adapters may have a role in thyroid carcinogenesis triggered by TRK oncogenes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586769     DOI: 10.1210/en.2002-221002

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Functional interaction between p75NTR and TrkA: the endocytic trafficking of p75NTR is driven by TrkA and regulates TrkA-mediated signalling.

Authors:  Lorena Perrone; Simona Paladino; Marialuisa Mazzone; Lucio Nitsch; Massimo Gulisano; Chiara Zurzolo
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

Review 2.  TRKing down an old oncogene in a new era of targeted therapy.

Authors:  Aria Vaishnavi; Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

3.  Role of STAT3 in in vitro transformation triggered by TRK oncogenes.

Authors:  Claudia Miranda; Tiziana Fumagalli; Maria Chiara Anania; Maria Grazia Vizioli; Sonia Pagliardini; Marco A Pierotti; Angela Greco
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

4.  Structural insights into FRS2α PTB domain recognition by neurotrophin receptor TrkB.

Authors:  Lei Zeng; Miklos Kuti; Shiraz Mujtaba; Ming-Ming Zhou
Journal:  Proteins       Date:  2014-07

Review 5.  NTRK fusion-positive cancers and TRK inhibitor therapy.

Authors:  Emiliano Cocco; Maurizio Scaltriti; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2018-12       Impact factor: 66.675

6.  Role and expression of FRS2 and FRS3 in prostate cancer.

Authors:  Tania Valencia; Ajay Joseph; Naveen Kachroo; Steve Darby; Susan Meakin; Vincent J Gnanapragasam
Journal:  BMC Cancer       Date:  2011-11-11       Impact factor: 4.430

Review 7.  Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers.

Authors:  Tingting Jiang; Guan Wang; Yao Liu; Lu Feng; Meng Wang; Jie Liu; Yi Chen; Liang Ouyang
Journal:  Acta Pharm Sin B       Date:  2020-05-23       Impact factor: 11.413

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.